Caspofungin Acetate

CHEMBL5314378 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
1213.4 g/mol
LogP
Phase
4

The acetate salt form of caspofungin, administered intravenously for serious invasive fungal infections including candidemia and invasive aspergillosis. It disrupts fungal cell wall integrity through inhibition of glucan synthesis. Liver function should be monitored during treatment, as dose adjustment may be needed in hepatic impairment.

น้ำหนักโมเลกุล

1213.4000 g/mol

TPSA

487.00 Ų

ด้านการรักษา

Pharmacokinetics (PK)

Pharmacodynamics (PD)

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(=O)O.CC(=O)O.CC[C@H](C)C[C@H](C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@H]([C@H](O)CCN)NC(=O)[C@H]([C@H](O)[C@@H](O)c2ccc(O)cc2)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@H]([C@@H](C)O)NC1=O

InChI

InChI=1S/C52H88N10O15.2C2H4O2/c1-5-28(2)24-29(3)12-10-8-6-7-9-11-13-39(69)56-34-26-38(68)46(55-22-21-54)60-50(75)43-37(67)19-23-61(43)52(77)41(36(66)18-20-53)58-49(74)42(45(71)44(70)31-14-16-32(64)17-15-31)59-48(73)35-25-33(65)27-62(35)51(76)40(30(4)63)57-47(34)72;2*1-2(3)4/h14-17,28-30,33-38,40-46,55,63-68,70-71H,5-13,18-27,53-54H2,1-4H3,(H,56,69)(H,57,72)(H,58,74)(H,59,73)(H,60,75);2*1H3,(H,3,4)/t28-,29+,30+,33+,34-,35-,36+,37-,38+,40-,41-,42-,43-,44-,45-,46-;;/m0../s1

Molecular Formula

C56H96N10O19

HBD / HBA

18 / 22

พันธะที่หมุนได้

23

อะตอมหนัก

85

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

The acetate salt form of caspofungin, administered intravenously for serious invasive fungal infections including candidemia and invasive aspergillosis. It disrupts fungal cell wall integrity through inhibition of glucan synthesis. Liver function should be monitored during treatment, as dose adjustment may be needed in hepatic impairment.

Yes, Caspofungin Acetate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL5314378. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 6850808. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.